The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low dens...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Heart J
Main Authors: Landlinger, Christine, Pouwer, Marianne G., Juno, Claudia, van der Hoorn, José W.A., Pieterman, Elsbet J., Jukema, J. Wouter, Staffler, Guenther, Princen, Hans M.G., Galabova, Gergana
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Basic Science
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5837708/
https://ncbi.nlm.nih.gov/pubmed/28637178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehx260
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados